Torii Pharmaceutical Co Ltd
TSE:4551
Torii Pharmaceutical Co Ltd
Income from Continuing Operations
Torii Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Income from Continuing Operations
¥5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥208.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥245.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥347.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥387.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
-¥57.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
5B
JPY
Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 5B JPY.
What is Torii Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
4%
Over the last year, the Income from Continuing Operations growth was 22%. The average annual Income from Continuing Operations growth rates for Torii Pharmaceutical Co Ltd have been 14% over the past three years , -29% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet